CT-2584

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C30H55N5O3
Molecular Weight	533.7894
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCCCCNCC(O)CCCCCCCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O

InChI

InChIKey=MZNMZWZGUGFQJP-UHFFFAOYSA-N

InChI=1S/C30H55N5O3/c1-4-5-6-7-8-9-10-13-16-19-22-31-24-26(36)21-18-15-12-11-14-17-20-23-35-29(37)27-28(32-25-33(27)2)34(3)30(35)38/h25-26,31,36H,4-24H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C30H55N5O3
Molecular Weight	533.7894
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11016649 | https://www.ncbi.nlm.nih.gov/pubmed/11575717 | https://www.ncbi.nlm.nih.gov/pubmed/9778687

CT-2584 is a cytotoxic agent which modulates intracellular metabolism of phosphatidic acid in tumor cells. CT-2884 inhibits CTP:choline-phosphate cytidylyltransferase and causes de novo phospholipid biosynthesis via phosphatidic acid to be shunted away from phosphatidylcholine and into phosphatidylinositol. CT-2884 induced cytotoxicity is associated with disruption and swelling of endoplasmic reticulum and mitochondria. In the early 2000s, CT-2584 was investigated in phase 2 clinical trials for the treatment of prostate cancer and soft-tissue sarcoma. No development of the drug was reported since.

Approval Year

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 02:18:22 GMT 2023` Edited by `admin` on `Sat Dec 16 02:18:22 GMT 2023`
Record UNII	67E5N3R22H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CT-2584

Common Name

English

1-(11-DODECYLAMINO-10-HYDROXYUNDECYL)-3,7-DIMETHYLXANTHINE

Systematic Name

English

CT 2584

Code

English

Code System Code Type Description

NCI_THESAURUS

C1729